文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Sorafenib in radioactive iodine-refractory
侵权投诉

Sorafenib in radioactive iodine-refractory

Sorafenib in radioactive iodine-refractory

OncoTargets and Therapy

Open Access Full Text Article

Dovepress

open access to scientific and medical research

Review

Sorafenib in radioactive iodine-refractory well-differentiated metastatic thyroid cancer

This article was published in the following Dove Press journal: OncoTargets and Therapy15 July 2014

Daniel C McFarland1

Krzysztof J Misiukiewicz2,3

Division of Hematology and Medical Oncology, Mount Sinai Medical

Center, New York, NY, USA; 2Division of Hematology and Medical Oncology, 3

Department of Otolaryngology, Mount Sinai Medical Center, Ruttenberg Treatment Center, New York, NY, USA

1

Abstract: Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of well-differentiated radioactive iodine-resistant metastatic thyroid cancer. This is the second drug in 40 years to be FDA approved for this indication. Recent reviews and a meta-analysis reveal a modest ability to induce a partial remis-sion but substantial ability to halt disease progression. Given the significant activating mutations present in thyroid cancer, many of which are inhibited by sorafenib, the next logical approach may be to combine targeted rational therapies if permitted by collective toxicity profiles. This systematic review aims to summarize the recent Phase II/III data leading to the FDA approval of sorafenib for radioactive iodine therapy differentiated thyroid cancer and highlights recent novel combination therapy trials.

Keywords: tyrosine kinase inhibitors, targeted therapy, RAI DTC, novel thyroid cancer treatment

Introduction

Recent Phase III data presented at the American Society of Clinical Oncology (ASCO) 2013 annual conference by Brose et al1 led to the US Food and Drug Administration (FDA) approval of sorafenib for the treatment of radioactive iodine-resistant (RAI-R) metastatic well-differentiated thyroid cancer (DTC). This is the second drug in 40 years to be FDA approved for this indication. Well-DTC is one of the fastest growing cancers in incidence.2,3 Historically, localized thyroid cancers have been treated by surgical resection and adjuvant thyroid ablative therapy which cures approximately 85% of papillary and follicular subtypes.4 Even with distant metastasis, it is still considered an indolent cancer usually until it loses its radioiodide avidity, which happens in roughly 30%–50% of metastatic cases.5 At that time, the 5-year survival of a patient with iodine-concentrating pulmonary metastasis goes from 60%–80% to roughly 30% for those tumors that do not take up iodine.6 Prior to November 2013, only one FDA-approved drug, doxorubicin, was being used to treat these patients but with a response rate of about 5% according to a recent analysis of modern radiographic images.7 Sorafenib was approved for the treatment of well-differentiated thyroid can-cer according to several Phase II studies and a Phase III study (Table 1) which have consistently shown the induction of stable disease (SD), and, less frequently, partial response (PR), in the setting of progressive metastatic DTC with predictable side effect profiles that are consistent with sorafenib use in other settings. Clinical testing of tyrosine kinase inhibitors (TKIs) began in the early 2000s and comes from the

Correspondence: Daniel McFarland Division of Hematology and Medical Oncology, Mount Sinai Medical Center, Box 1079, One Gustave Levy Place, New York, NY 10029, USA

email daniel.mcfarland@mountsinai.org

Sorafenib in radioactive iodine-refractory

第1页

你可能喜欢

热门文档

相关文档

  • Pipeline on the move

    differentiated thyroid carcinoma refractory to to radioactive iodine treatment....Tablets, eq 200 mg sorafenib. Prophylaxis of invasive Aspergillus and Candida...

  • 【论文】The multikinase inhibitor sorafenib induces...

    The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer_专业资料。Asa orafdooy(001:2-3 inJunlAnrlg21)25754o@2 ASIM...

  • Pipeline on the move

    differentiated thyroid carcinoma refractory to to radioactive iodine treatment....Tablets, eq 200 mg sorafenib. Prophylaxis of invasive Aspergillus and Candida...

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email